Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
Humacyte, Inc. (HUMA)
Company Research
Source: GlobeNewswire
- Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. - - He will work with the Company’s leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte’s broad pipeline - DURHAM, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has appointed Rick McElheny to the role of Senior Vice President of Business Development. Mr. McElheny will work with the Company’s leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte ‘s broad regenerative medicine pipeline. “We are delighted to welcome Rick to our team at such an exciting and transformative moment for the Humacyte,” said Laura Nilason, Founder and Chief Executive Office
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.MarketBeat
- Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Humacyte (HUMA) had its price target lowered by BTIG Research from $6.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
HUMA
Earnings
- 3/27/26 - In-Line
HUMA
Sec Filings
- 3/27/26 - Form 10-K
- 3/24/26 - Form SCHEDULE
- 3/19/26 - Form 8-K
- HUMA's page on the SEC website